Fingerprint
Dive into the research topics of 'A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: An Eastern Cooperative Oncology Group study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically